DARAPRIM (pyrimethamine) is an antiparasitic compound available
in tablet form for oral administration.
Treatment of Toxoplasmosis: DARAPRIM is indicated for the treatment of toxoplasmosis
when used conjointly with a sulfonamide, since synergism exists
with this combination.
Treatment of Acute Malaria: DARAPRIM is also indicated for the treatment of acute
malaria. It should not be used alone to treat acute malaria.
Fast-acting schizonticides such as chloroquine or quinine are
indicated and preferable for the treatment of acute malaria.
However, conjoint use of DARAPRIM with a sulfonamide (e.g.,
sulfadoxine) will initiate transmission control and suppression
of susceptible strains of plasmodia.
Chemoprophylaxis of Malaria: DARAPRIM is indicated for the chemoprophylaxis of malaria
due to susceptible strains of plasmodia. However, resistance to
pyrimethamine is prevalent worldwide. It is not suitable as a
prophylactic agent for travelers to most areas.
Published Studies Related to Daraprim (Pyrimethamine)
Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. [2011.09.21]
BACKGROUND: Sulphadoxine-pyrimethamine, in combination with artesunate or amodiaquine, is recommended for the treatment of uncomplicated malaria and is being evaluated for intermittent preventive treatment. Yet, limited data is available on pharmacokinetic interactions between these drugs... CONCLUSION: Despite slight differences in pyrimethamine volumes of distribution and elimination half-life, these data show similar exposure to SP over the critical initial seven days of treatment and support the current use of SP in combination with either AQ or AS for uncomplicated falciparum malaria treatment in young Malian children.
Superiority of 3 over 2 doses of intermittent preventive treatment with sulfadoxine-pyrimethamine for the prevention of malaria during pregnancy in mali: a randomized controlled trial. [2011.08.01]
BACKGROUND: In 2003, Mali introduced intermittent preventive therapy in pregnancy (ITPp) with sulfadoxine-pyrimethamine (SP) for the control of malaria in pregnancy, consisting of 2 doses of SP given in the 2nd and 3rd trimester. This widely used regimen, although very effective, leaves many women unprotected from malaria during the last 4-to-8 weeks of gestation, which is a pivotal period for fetal weight gain. The aim of the study was to compare the efficacy and safety of 3-dose versus 2-dose IPTp-SP for the prevention of placental malaria and associated low birth weight (LBW)... CONCLUSIONS: Adding a third dose of ITPp-SP halved the risk of placental malaria, LBW, and preterm births in all gravidae, compared with the standard 2-dose regimen, in this area of highly seasonal transmission with low levels of SP resistance. Clinical Trials Registration: ISRCTN 74189211.
Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy. [2011.04]
Intermittent preventive treatment in infancy (IPTi) entails routine administration of antimalarial treatment doses at specified times in at-risk infants...
Population pharmacokinetics of sulfadoxine and pyrimethamine in Malawian children with malaria. [2011.02]
In addition to parasite resistance, inadequate levels of exposure to antimalarial drugs may contribute to treatment failure. We developed population pharmacokinetic (PK) models to describe the distribution of sulfadoxine (SDX) and pyrimethamine (PYM) in children with uncomplicated malaria in Malawi...
Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. [2011.01]
PURPOSE: To compare the efficacy of intravitreal injection of clindamycin and dexamethasone with classic treatment for ocular toxoplasmosis... CONCLUSIONS: Intravitreal injection of clindamycin and dexamethasone may be an acceptable alternative to the classic treatment in ocular toxoplasmosis. It may offer the patient more convenience, a safer systemic side effect profile, greater availability, and fewer follow-up visits and hematologic evaluations. Copyright (c) 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Clinical Trials Related to Daraprim (Pyrimethamine)
Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease) [Completed]
The objectives of this clinical trial are to assess the safety and tolerability, as well as
efficacy, of a stepwise dosing regimen of pyrimethamine, starting at 25 mg/day, given as a
single dose daily for 4 weeks in patients affected with chronic Tay-Sachs or Sandhoff
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Recruiting]
In this research study we will start by looking for the highest dose of pyrimethamine that
can be given safely to CLL patients without severe or unmanageable side effects. This dose
will then be used for a larger Phase II study to assess the efficacy of pyrimethamine for
the treatment of CLL/SLL. Pyrimethamine is an antibiotic that is used for the treatment of
certain infections. Previous research studies have shown that pyrimethamine may target a
protein in tumor cells, called STAT3, which may be important for the growth of chronic
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) cells. Pyrimethamine can kill
CLL/SLL cells in the laboratory, and we are therefore undertaking this study to assess
whether pyrimethamine will result in clinical benefit or tumor responses in CLL in patients.
Prevention of Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy [Recruiting]
Background : When a mother contracts toxoplasmosis during pregnancy, the parasite may be
transmitted from to her unborn child. This results in congenital toxoplasmosis, which may
cause damage to the eyes and nervous system of the child. To date, no method has been proved
effective to prevent this transmission. In France, spiramycin is usually prescribed to women
who have toxoplasma seroconversion in pregnancy, however its efficacy has not been
determined. The standard treatment for toxoplasmosis is the combination of the antiparasitic
drugs pyrimethamine and sulfadiazine, but this strategy has not been evaluated for the
prevention of mother-to-child transmission.
Purpose : Randomized phase 3 trial to determine whether pyrimethamine + sulfadiazine is
more effective than spiramycin to prevent congenital toxoplasmosis.
Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction of Pyrimethamine and Metformin IR [Completed]
Therapeutic Efficacy Study of Pyrimethamine/Sulfdoxine (Fansidar®) for the Treatment of Uncomplicated Falciparum Malaria in the Peruvian Amazon [Completed]
The purpose of this study is to determine the efficacy of pyrimethamine/sulfdoxine
(Fansidar®) for the treatment of uncomplicated falciparum malaria in the Peruvian Amazon.
Reports in the mid 1990s indicated that Fansidar was failing to cure patients with confirmed
falciparum malaria. The study design was based on accepted WHO parasitological and clinical
outcomes to determine the overall efficacy of Fansider and inform the Peruvian National
Malaria Control authorities as to the continued wisdom of recommending Fansidar as first
line treatment for uncomplicated falciparum malaria in the Peruvian Amazon.
Page last updated: 2011-12-09